We read with interest the meta-analysis and indirect comparison of levetiracetam and brivaracetam recently presented by Zhang et al. (Seizure 2016;39:28–33) . We would like to raise two points in response. Firstly, some methodological elements common to indirect comparisons have not been addressed in the published work. Secondly, the use of network meta-analyses of clinical trials to produce valid evidence of the comparative efficacy and safety of antiepileptic drugs (AEDs) has previously been called into question, which was not discussed by the authors.